Epitope Mapping of Rituximab Using HisMAP Method

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


CD20 is expressed in the B lymphocyte, and an effective target for the detection and treatment of B cell lymphomas. Therefore, CD20 has been studied as a therapeutic target of B cell lymphomas and autoimmune disorders. Specific anti-CD20 monoclonal antibodies (mAbs), such as rituximab, ofatumumab, veltuzumab, and ocaratuzumab, have been developed. Revealing the recognition mechanism of antigen by mAbs could contribute to understanding the function of mAbs and could be useful for the development of vaccine. Rituximab is a mouse-human chimeric anti-CD20 mAb, which was developed and approved for the treatment of the B cell malignancies. Hence, the binding epitope of rituximab for CD20 has been studied. Some reports show that 170-ANPS-173, especially Ala170 and Pro172 of CD20 are important for rituximab binding. However, only phage display results showed that 182-YCYSI-186 of CD20 is also important for rituximab binding to CD20. In this study, we tried to determine the binding epitope of rituximab for CD20 using histidine-tag insertion for epitope mapping (HisMAP) method. The results showed that two regions of CD20 (169-PANPSE-174 and 183-CYSIQ-187) are important for rituximab-binding for CD20.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Issue number1
Publication statusPublished - 2022 Feb 1


  • CD20
  • Epitope mapping
  • His tag
  • Monoclonal antibody
  • Rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Epitope Mapping of Rituximab Using HisMAP Method'. Together they form a unique fingerprint.

Cite this